WA-SPIE
12.1.2021 18:11:31 CET | Business Wire | Press release
The Awards Committee of SPIE, the international society for optics and photonics , today announced the recipients of its prestigious annual awards . Honoring transformative advancements in multiple areas — including medicine, astronomy, lithography, optical metrology, and community-focused achievements — the Society's awards recognize technical accomplishments as well as committed service to SPIE and support of its organizational mission.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005279/en/
SPIE Gold Medal: Hugo Thienpont
In recognition of his profound and durable impact on society and pioneering vision for photonics. The different disruptive instruments that Thienpont has developed and implemented during the past decades have generated a tangible impact on education, research, innovation, and societal well-being in Flanders, across Europe, and beyond.
SPIE President's Award: Maria Yzuel
In recognition of her inspirational leadership in the field of optics; tireless dedication to the promotion of equity, diversity, and inclusion in science; and many years of outstanding service to SPIE and its international community.
SPIE Directors' Award: Maryellen Giger
In recognition of her outstanding service to SPIE and the optics and photonics communities. Giger has been a key voice in data-driven approaches, and an active leader in pushing forward our equity, diversity, and inclusion efforts.
SPIE Mozi Award: Xiang Zhang
In recognition of his seminal, fundamental contributions in optical physics and experimental research in the optical perfect lens.
SPIE Britton Chance Award in Biomedical Optics: Enrico Gratton
In recognition of a lifetime of contributions to the field of biomedical optics, including pioneering theoretical and instrumentation developments in fluorescence spectroscopy, fluorescence microscopy, and diffuse medical imaging.
SPIE Biophotonics Technology Innovator Award: Keisuke Goda
In recognition of his significant contributions to the field of biophotonics through the development of innovative ultrafast optical imaging and spectroscopy methods and their integration into microfluidic platforms.
SPIE A.E. Conrady Award in Optical Engineering: Dave Aikens
In recognition of his world-leading expertise, training programs, and development of optical engineering and optical standards.
SPIE Harrison H. Barrett Award in Medical Imaging: Kevin Berbaum
In recognition of more than three decades of dedication in the study of Satisfaction of Search, and significant contributions to receiver operating characteristic analysis.
SPIE Harold E. Edgerton Award in High-Speed Optics: Vladislav Yakovlev
In recognition of his remarkable contributions to ultrafast laser technology, ultrafast spectroscopies, and ultrafast imaging and their applications, as well as for his SPIE outreach.
SPIE Dennis Gabor Award in Diffractive Optics:
Małgorzata Kujawińska
In recognition of her outstanding and manifold contributions to holographic technologies in optical metrology, optical imaging, and optical information processing, as well as for her extraordinary dedication to the SPIE community and widely recognized international leadership in applied optical engineering.
SPIE George W. Goddard Award in Space and Airborne Optics: Thomas Rimmele
In recognition of his invention and application of extended-source adaptive optics delivering diffraction-limited, high-resolution imaging of the solar surface.
SPIE G. G. Stokes Award in Optical Polarization: Nirmalya Ghosh
In recognition of his extensive research in the field of Mueller matrix polarimetry and applications of Mueller matrix polarimetric spectroscopy and imaging in various interdisciplinary fields including quantum optics, space optics, biomedical optics, chemistry, material science, and fluorescence spectroscopy.
SPIE Chandra S. Vikram Award in Optical Metrology: Krzysztof Patorski
In recognition of his
seminal contributions to diffraction, interferometry, moiré fields, and fringe analysis with applications in optical metrology, experimental mechanics, and biomedical engineering.
SPIE Frits Zernike Award in Microlithography: Bruce Smith
In recognition of his many contributions as a researcher and leader in the microlithography community, and for his achievements in educating an entire generation of engineers who continue to advance academic research and industry understanding.
SPIE Diversity Outreach Award: Celine d'Orgeville
In recognition of her leadership in diversity, inclusion, and equity activities in Australia and elsewhere in the world.
SPIE Maria Goeppert-Mayer Award in Photonics: Jorge Ojeda-Castañeda
In recognition of his outstanding contributions to modern and advanced imaging technologies for the development of phase-space representations of imaging devices, which enable the design of innovative techniques for extending field depth, and for proposing novel designs employing lenses with tunable optical power.
SPIE Maiman Laser Award: Anne Tropper
In recognition of her pioneering contributions to rare-earth doped fiber and optically pumped semiconductor lasers.
SPIE Early Career Achievement Award — Academic Focus: Muyinatu Bell
In recognition of her pioneering contributions to photoacoustic imaging for surgical guidance, including innovative technology designs, novel deep learning applications, informative spatial coherence beamforming theory, and visionary clinical possibilities.
SPIE Early Career Achievement Award — Industry/Government Focus: Sergio Carbajo
In recognition of his capacity to unify ultrafast and quantum optics with X-ray science to advance the mission of Basic Energy Sciences facilities.
SPIE Maria J. Yzuel Educator Award: Bishnu Pal
In recognition of four decades of sustained contributions in education, outreach, research, technical program committees of global flagship conferences, and editing of four popular publications in guided wave optics and photonics.
SPIE Aden and Marjorie Meinel Technology Achievement Award: Shouleh Nikzad
In recognition of her pioneering and sustained contributions to the development of ultraviolet instrument technologies, especially imagers for space exploration and extension of their use in terrestrial applications.
The complete listing of all SPIE awards and recipients is available here .
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5.8 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005279/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom